HK1090571A1 - Methods for preventing mitochondrial permeability transition - Google Patents

Methods for preventing mitochondrial permeability transition

Info

Publication number
HK1090571A1
HK1090571A1 HK06112161.2A HK06112161A HK1090571A1 HK 1090571 A1 HK1090571 A1 HK 1090571A1 HK 06112161 A HK06112161 A HK 06112161A HK 1090571 A1 HK1090571 A1 HK 1090571A1
Authority
HK
Hong Kong
Prior art keywords
methods
permeability transition
mitochondrial permeability
preventing mitochondrial
preventing
Prior art date
Application number
HK06112161.2A
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Priority to HK09110947.4A priority Critical patent/HK1131995A1/xx
Publication of HK1090571A1 publication Critical patent/HK1090571A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
HK06112161.2A 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition HK1090571A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number Publication Date
HK1090571A1 true HK1090571A1 (en) 2006-12-29

Family

ID=32853391

Family Applications (6)

Application Number Title Priority Date Filing Date
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK06112161.2A HK1090571A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition

Family Applications After (4)

Application Number Title Priority Date Filing Date
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Country Status (14)

Country Link
US (8) US7576061B2 (xx)
EP (9) EP2656854B1 (xx)
JP (7) JP4838114B2 (xx)
CN (3) CN102784383B (xx)
AU (1) AU2004209663B2 (xx)
CA (1) CA2515080C (xx)
CY (2) CY1114959T1 (xx)
DK (3) DK2656854T3 (xx)
ES (3) ES2436011T3 (xx)
HK (6) HK1131995A1 (xx)
HU (1) HUE027110T2 (xx)
PT (2) PT2656854E (xx)
SI (1) SI2656854T1 (xx)
WO (1) WO2004070054A2 (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2656854T3 (en) * 2003-02-04 2015-07-06 Cornell Res Foundation Inc Applications of an aromatic-cationic peptide
BRPI0409911A (pt) * 2003-05-01 2006-04-25 Cornell Res Foundation Inc método para liberar uma molécula em uma célula, e, complexo carreador
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
SI2252312T1 (sl) 2008-02-07 2014-08-29 Cornell University, Postopki za preprečevanje ali zdravljenje insulinske rezistence
WO2009108695A2 (en) 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
HUE029550T2 (en) * 2009-08-12 2017-03-28 Univ Cornell Methods of preventing or treating metabolic syndrome
PT2470191E (pt) 2009-08-24 2014-06-12 Stealth Peptides Int Inc Métodos e composições para prevenção ou tratamento de doenças oftálmicas
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHODS OF REALIZING AORTO-CORONARY BRIDGE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
AU2011207432A1 (en) * 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9345738B2 (en) * 2010-07-09 2016-05-24 Stealth Biotherapeutics Corp. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
CN107219358A (zh) * 2011-03-24 2017-09-29 康奈尔大学 芳香族阳离子肽及其用途
CN103889993B (zh) * 2011-09-19 2017-05-31 吉奇亚公司 修饰的肌酸化合物
US9988422B2 (en) 2011-09-29 2018-06-05 Stealth Biotherapeutics Corp Aromatic-cationic peptides and methods for using same
EP2768516A4 (en) * 2011-10-17 2015-08-19 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3656394A1 (en) * 2011-12-09 2020-05-27 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2014022551A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP2908839B1 (en) * 2012-10-22 2019-08-21 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
JP6839490B2 (ja) 2013-03-01 2021-03-10 ステルス バイオセラピューティックス コープ ミトコンドリア疾患の治療のための方法
CN105407906A (zh) 2013-03-01 2016-03-16 康德生物医疗技术公司 预防或治疗巴斯综合征的方法和组合物
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
US20160375088A1 (en) * 2013-09-30 2016-12-29 Brian Yinge ZHAO Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
AU2015274367B2 (en) 2014-06-13 2020-11-26 Beth Israel Deaconess Medical Center, Inc. Products and methods to isolate mitochondria
PL3160984T3 (pl) 2014-06-25 2021-10-25 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu
SI3160985T1 (sl) 2014-06-30 2021-11-30 Flamma S.P.A. Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3473253A1 (en) 2014-10-29 2019-04-24 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
JP6427691B2 (ja) 2016-11-30 2018-11-21 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2019033330A1 (en) 2017-08-17 2019-02-21 Xw Laboratories, Inc. PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
EP3988561B1 (en) 2017-09-04 2023-06-07 XWPharma Ltd. Preparation and use of reactive oxygen species scavenger
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
JP2022511939A (ja) * 2018-12-18 2022-02-01 ステルス バイオセラピューティクス コーポレーション ミトコンドリア標的化ペプチド
US20220347212A1 (en) * 2019-05-02 2022-11-03 Children`S Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
JP2023541403A (ja) 2020-09-09 2023-10-02 ソーシャル・プロフィット・ネットワーク ビオチンをミトコンドリアに送達するための方法及び組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ATE136905T1 (de) 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
DK0511317T3 (da) * 1990-01-17 1999-01-25 Univ California Sammensætning til forbedring af overlevelsen af biologiske materialer
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
NZ335610A (en) * 1996-10-07 2000-10-27 Lilly Co Eli Phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazole compounds useful as neuro-protective agents
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
AU1818299A (en) * 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7856600A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
AU2001277908A1 (en) * 2000-07-18 2002-01-30 Cornell Research Foundation Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
JP2004523490A (ja) * 2000-11-28 2004-08-05 ギルフォード ファーマシュウティカルズ インコーポレイテッド 二置換カルボサイクリックサイクロフィリン結合化合物とその用途
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
JP4125125B2 (ja) * 2001-02-16 2008-07-30 コーディス・コーポレイション ステントデリバリ装置の製造方法
WO2002074194A2 (en) * 2001-03-16 2002-09-26 Sts Biopolymers, Inc. Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
DK2656854T3 (en) * 2003-02-04 2015-07-06 Cornell Res Foundation Inc Applications of an aromatic-cationic peptide
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
BRPI0409911A (pt) 2003-05-01 2006-04-25 Cornell Res Foundation Inc método para liberar uma molécula em uma célula, e, complexo carreador
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression

Also Published As

Publication number Publication date
AU2004209663A1 (en) 2004-08-19
PT1599216E (pt) 2013-12-17
HK1190930A1 (en) 2014-07-18
EP2865385A1 (en) 2015-04-29
CA2515080A1 (en) 2004-08-19
US20230293624A1 (en) 2023-09-21
AU2004209663A2 (en) 2004-08-19
CN102617706A (zh) 2012-08-01
JP6126059B2 (ja) 2017-05-10
ES2540897T3 (es) 2015-07-14
JP5775285B2 (ja) 2015-09-09
JP2019089773A (ja) 2019-06-13
DK2656854T3 (en) 2015-07-06
JP2015007127A (ja) 2015-01-15
JP2011026346A (ja) 2011-02-10
US20040248808A1 (en) 2004-12-09
EP3479838A1 (en) 2019-05-08
EP2491943B1 (en) 2018-10-10
EP1599216B1 (en) 2013-11-06
ES2436011T3 (es) 2013-12-26
JP2015180693A (ja) 2015-10-15
US8957030B2 (en) 2015-02-17
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
US7718620B2 (en) 2010-05-18
EP3144009A1 (en) 2017-03-22
JP6166312B2 (ja) 2017-07-19
US20130244957A1 (en) 2013-09-19
EP2656854A1 (en) 2013-10-30
WO2004070054A2 (en) 2004-08-19
DK1599216T3 (da) 2013-12-09
US7576061B2 (en) 2009-08-18
EP1599216B9 (en) 2015-02-11
HUE027110T2 (en) 2016-08-29
CY1116575T1 (el) 2017-03-15
CN104225574B (zh) 2017-01-11
EP3842055A1 (en) 2021-06-30
CA2515080C (en) 2012-04-10
CN102784383A (zh) 2012-11-21
JP2017095519A (ja) 2017-06-01
US20120021970A1 (en) 2012-01-26
PT2656854E (pt) 2015-09-03
AU2004209663B2 (en) 2009-01-15
US20100190718A1 (en) 2010-07-29
HK1178794A1 (en) 2013-09-19
EP1599216A2 (en) 2005-11-30
JP2013249313A (ja) 2013-12-12
EP3305313A1 (en) 2018-04-11
EP2656854B1 (en) 2015-05-20
US20070027087A1 (en) 2007-02-01
WO2004070054A3 (en) 2005-04-14
EP2491943A3 (en) 2013-01-23
US8404646B2 (en) 2013-03-26
HK1204999A1 (en) 2015-12-11
DK2865385T3 (en) 2016-12-19
EP2865385B1 (en) 2016-11-16
CN104225574A (zh) 2014-12-24
JP2006516652A (ja) 2006-07-06
ES2605504T3 (es) 2017-03-14
US20200038472A1 (en) 2020-02-06
SI2656854T1 (sl) 2015-09-30
US20150359838A1 (en) 2015-12-17
HK1209652A1 (en) 2016-04-08
CN102784383B (zh) 2014-09-17
EP1599216A4 (en) 2009-11-11
EP3659618A1 (en) 2020-06-03
JP5837542B2 (ja) 2015-12-24
JP4838114B2 (ja) 2011-12-14

Similar Documents

Publication Publication Date Title
HK1204999A1 (en) Methods for preventing mitochondrial permeability transition
GB2401643B (en) Padlock
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
PT1682493E (pt) Derivados de aminoacetonitrilo
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
GB0326439D0 (en) Methods
AU155985S (en) Beaker
SI1599216T1 (sl) Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
PT1706373E (pt) Derivados de amidoacetonitrilo
GB0328243D0 (en) Methods
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0327909D0 (en) Methods
GB0320627D0 (en) Methods
GB0327368D0 (en) Methods
GB0315827D0 (en) Methods
GB0305252D0 (en) Methods
GB0323793D0 (en) Methods
GB0307076D0 (en) Methods
GB0328747D0 (en) Methods
AU2003280821A8 (en) Beauveriolide derivative
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
GB0330078D0 (en) Methods

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240202